Progyny, Inc. (NASDAQ:PGNY) Receives $25.83 Consensus PT from Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have received a consensus rating of “Hold” from the thirteen brokerages that are covering the company, MarketBeat reports. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $24.82.

Several research firms have recently commented on PGNY. Bank of America upped their price target on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. upped their target price on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Truist Financial reiterated a “hold” rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Barclays cut their price objective on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Finally, Canaccord Genuity Group raised their target price on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday.

Insiders Place Their Bets

In related news, CEO Peter Anevski bought 209,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the transaction, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman David J. Schlanger bought 150,000 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The shares were bought at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the purchase, the chairman now directly owns 228,269 shares of the company’s stock, valued at $3,350,988.92. This represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PGNY. Mackenzie Financial Corp lifted its position in shares of Progyny by 423.8% in the fourth quarter. Mackenzie Financial Corp now owns 117,387 shares of the company’s stock worth $2,025,000 after buying an additional 94,978 shares in the last quarter. AWM Investment Company Inc. increased its stake in Progyny by 540.0% in the 4th quarter. AWM Investment Company Inc. now owns 160,000 shares of the company’s stock worth $2,760,000 after acquiring an additional 135,000 shares during the last quarter. Voloridge Investment Management LLC increased its stake in Progyny by 85.5% in the 4th quarter. Voloridge Investment Management LLC now owns 1,197,993 shares of the company’s stock worth $20,665,000 after acquiring an additional 552,066 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Progyny by 83.8% during the 4th quarter. Two Sigma Advisers LP now owns 266,100 shares of the company’s stock worth $4,590,000 after acquiring an additional 121,300 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Progyny by 15.9% during the 4th quarter. Two Sigma Investments LP now owns 657,276 shares of the company’s stock valued at $11,338,000 after acquiring an additional 90,197 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Performance

PGNY stock opened at $22.53 on Friday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of 38.85, a P/E/G ratio of 2.39 and a beta of 1.34. The business’s 50-day moving average is $20.68 and its two-hundred day moving average is $18.67. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $38.98.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.